CLDX stock news · Celldex Therapeutics, Inc.
Get alerts for CLDX
Follow Celldex Therapeutics, Inc. (CLDX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CLDXFree on the App Store and Google Play, or on the web.
H.C. Wainwright cut its price target for Celldex Therapeutics from $64.00 to $58.00 but still rates it a 'Buy.
NeutralH.C. Wainwright cut its Celldex share-price target from $64 to $58 but kept its Buy rating.
Celldex said its Phase 2 study of barzolvolimab for atopic dermatitis did not achieve its main goals.
Bad for CLDXCelldex's Phase 2 atopic dermatitis study missed its main measures and its bar for continued work. This is bad news for that use, despite earlier positive results elsewhere.
Celldex Therapeutics, Inc. shares news about its Barzolvolimab trials for chronic hives.
NeutralThe filing attaches a press release about two Phase 3 trials but contains no trial results. It does not change Celldex's outlook.